Search

Displaying results 3671 - 3680 of 8974 in total
  1. Drug

    Uric acid

    go.drugbank.com/drugs/DB08844
    Investigational

    At present (August 2013), there is no approved formulation or indication for uric acid. … Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … Inhibiting this enzyme results in a decrease of bile acids returning to the liver, which is helpful for the treatment of NASH as abnormal cholesterol metabolism and accumulation of free cholesterol in

  3. Drug

    TRGFT-201

    go.drugbank.com/drugs/DB23064
    ApprovedInvestigational

    [L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … Orca-T (allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq) is a donor-derived allogeneic cell therapy used in matched-donor hematopoietic stem cell transplantation for adults with blood

    International brands: ORCA-T
  4. Drug

    Atriplex polycarpa pollen

    go.drugbank.com/drugs/DB10756
    Approved

    Atriplex polycarpa pollen is the pollen of the Atriplex polycarpa plant. Atriplex polycarpa pollen is mainly used in allergenic testing.

    Mixtures: Scale Atriplex Mix, Scale Atriplex Mix
  5. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. … The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.

  6. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

  7. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

    Categories: Antihistamines for Systemic Use
  8. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

  9. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases.

  10. Drug

    Safrazine

    go.drugbank.com/drugs/DB09253
    ApprovedWithdrawn

    In 1960, it was used as an antidepressant but it is now discontinued.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome